title: Plasma concentrations of an angiotensin-converting enzyme inhibitor, benazepril, and its active metabolite, benazeprilat, after repeated administrations of benazepril in dogs with experimental kidney impairment.
abstract: In order to examine the safety of an angiotensin-converting enzyme (ACE) inhibitor in dogs with impaired renal excretion route, benazepril was administered orally, and plasma concentrations of benazeprilat, the active metabolite of benazepril, were determined in dogs with renal mass reduction (1/4th kidney) created by right-side nephrectomy and ligation of branches of the left renal arteries. Five dogs were administered benazepril orally at a given dose (0.5 mg/kg body weight) and 4 other dogs received 20 times that dose (10 mg/kg body weight) once daily for 15 consecutive days before (intact kidney period) and after (1/4th kidney period) creation of kidney impairment. Six control dogs received surgical treatment, but no drug. After creating a 1/4th kidney, plasma urea nitrogen and creatinine concentrations increased to approximately 30 mg/dl and 2.0 mg/dl, respectively, and renal plasma flow and glomerular filtration rate decreased to 37% and 30% of pre-treatment values, respectively. However, these parameters did not change significantly during the 1/4th kidney period both in the 0.5 mg/kg and 10 mg/kg groups. In the 0.5 mg/kg group, plasma benazeprilat concentrations increased to approximately 20 ng/ml to 340 ng/ml 2 hr after each administration, and there were no significant differences between the plasma benazeprilat concentrations during the intact and 1/4th kidney periods. In the 10 mg/kg group, plasma benazeprilat concentrations varied in the individual dog, but did not increase with the days of administration, and were not significantly different on each administration day between the intact and 1/4th kidney periods in either dose group. The AUCs(0-24) of plasma benazeprilat concentrations determined on the 15th administration day were not different between the intact and 1/4th kidney periods in dogs of either dose group. Plasma ACE activities decreased after drug administration in dogs of both groups. Benazepril seemed to have a high safety, and the adjustment of dosage regimen might not be needed in dogs with mild to moderate renal function impairment because the drug was excreted both from the kidneys and liver.
authors.affiliation: Division of Veterinary Medicine, Faculty of Agriculture, Gifu University, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kitagawa
authors.forename: T
authors.initials: T
authors.lastname: Eguchi
authors.forename: K
authors.initials: K
authors.lastname: Kitoh
authors.forename: Y
authors.initials: Y
authors.lastname: Ohba
authors.forename: M
authors.initials: M
authors.lastname: Kondo
authors.forename: M
authors.initials: M
authors.lastname: Nakano
authors.forename: Y
authors.initials: Y
authors.lastname: Sasaki
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000097:blood*; D000818:Animals; D001552:Benzazepines / Q000008:administration & dosage* / Q000097:blood*; D001794:Blood Pressure; D004283:Dog Diseases / Q000097:blood*; D004285:Dogs; D005260:Female; D005919:Glomerular Filtration Rate; D007674:Kidney Diseases / Q000097:blood / Q000662:veterinary*; D008297:Male
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001552:Benzazepines; C052133:benazeprilat; C044946:benazepril